1642152-40-6

1642152-40-6 structure

Name: Trastuzumab duocarmazine
Chemical Name: Trastuzumab duocarmazine
CAS Number: 1642152-40-6
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-01-26 14:37:13
Modify Date: 2024-01-15 11:50:37
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1].

Name	Trastuzumab duocarmazine

Description	Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1].
Related Catalog	Research Areas >> Cancer
In Vitro	Trastuzumab duocarmazine (SYD985) (0.0001-100 μg/mL, 24 h) 对 HER2- 和 HER2+ 细胞都有杀伤力，与作用于 T-DM1 的 IC50 值为 0.096 μg/mL 相比，对 HER2/NEU3+ 细胞系的杀伤力要高出 7 倍，IC50值为 0.013 μg/mL。更重要的是，在 HER2/NEU1+ 细胞中，它的杀伤力是 T-DM1 的 54 倍[1]。
In Vivo	Trastuzumab duocarmazine (SYD985) (3 mg/kg or 10 mg/kg, i.v., once) 均可以显著抑制肿瘤的生长，延长小鼠的生存周期，具有有效的体内抗肿瘤活性[1]。
References	[1]. Gulden Menderes, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res. 2017 Oct 1;23(19):5836-5845.

No Any Chemical & Physical Properties